JP2016521755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521755A5 JP2016521755A5 JP2016519696A JP2016519696A JP2016521755A5 JP 2016521755 A5 JP2016521755 A5 JP 2016521755A5 JP 2016519696 A JP2016519696 A JP 2016519696A JP 2016519696 A JP2016519696 A JP 2016519696A JP 2016521755 A5 JP2016521755 A5 JP 2016521755A5
- Authority
- JP
- Japan
- Prior art keywords
- metabolic disorder
- composition
- antagonist
- major component
- sumn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 13
- 102000005962 receptors Human genes 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000000556 agonist Substances 0.000 claims description 7
- 102000003678 AMPA Receptors Human genes 0.000 claims description 4
- 108090000078 AMPA Receptors Proteins 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 229940044601 receptor agonist Drugs 0.000 claims description 4
- 239000000018 receptor agonist Substances 0.000 claims description 4
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 claims description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims 31
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 22
- 239000000774 AMPA receptor agonist Substances 0.000 claims 14
- 239000003140 4 aminobutyric acid A receptor blocking agent Substances 0.000 claims 12
- 239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 claims 12
- 229940124118 AMPA receptor agonist Drugs 0.000 claims 11
- 229960003638 dopamine Drugs 0.000 claims 9
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 7
- 208000008589 Obesity Diseases 0.000 claims 7
- 208000001280 Prediabetic State Diseases 0.000 claims 7
- 235000020824 obesity Nutrition 0.000 claims 7
- 201000009104 prediabetes syndrome Diseases 0.000 claims 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 6
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 6
- 210000005064 dopaminergic neuron Anatomy 0.000 claims 5
- 230000008499 blood brain barrier function Effects 0.000 claims 4
- 210000001218 blood-brain barrier Anatomy 0.000 claims 4
- 210000002569 neuron Anatomy 0.000 claims 4
- 230000033764 rhythmic process Effects 0.000 claims 4
- 230000037007 arousal Effects 0.000 claims 3
- 230000003371 gabaergic effect Effects 0.000 claims 3
- 210000000221 suprachiasmatic nucleus Anatomy 0.000 claims 3
- 230000005856 abnormality Effects 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000006742 locomotor activity Effects 0.000 claims 2
- 230000035699 permeability Effects 0.000 claims 2
- 206010062519 Poor quality sleep Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 230000027288 circadian rhythm Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 210000002445 nipple Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000002618 waking effect Effects 0.000 claims 1
- -1 amide phosphate derivatives Chemical class 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- SULXXKLCQRXMHP-UHFFFAOYSA-N 4-[1-hydroxy-5-(3-phenylphenyl)pyrazol-4-yl]piperidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC(C=2C=CC=CC=2)=CC=1C=1N(O)N=CC=1C1CCNCC1 SULXXKLCQRXMHP-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 2
- OMCYEZUIYGPHDJ-OQLLNIDSSA-N chembl354261 Chemical compound OC1=CC=CC=C1\C=N\NC(=O)C1=CC=CC=C1O OMCYEZUIYGPHDJ-OQLLNIDSSA-N 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical compound NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 description 2
- RLJKFAMYSYWMND-GRTNUQQKSA-M (6r)-6-[(5s)-6,6-dimethyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-5-yl]-6h-furo[3,4-g][1,3]benzodioxol-8-one;chloride Chemical compound [Cl-].O([C@H]1[C@@H]2C3=CC=4OCOC=4C=C3CC[N+]2(C)C)C(=O)C2=C1C=CC1=C2OCO1 RLJKFAMYSYWMND-GRTNUQQKSA-M 0.000 description 1
- HKJKCPKPSSVUHY-GRTNUQQKSA-M (6r)-6-[(5s)-6,6-dimethyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-5-yl]-6h-furo[3,4-g][1,3]benzodioxol-8-one;iodide Chemical compound [I-].O([C@H]1[C@@H]2C3=CC=4OCOC=4C=C3CC[N+]2(C)C)C(=O)C2=C1C=CC1=C2OCO1 HKJKCPKPSSVUHY-GRTNUQQKSA-M 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical class O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 description 1
- IAWXTSMHXFRLQR-UHFFFAOYSA-N 2,3-bis($l^{1}-oxidanyl)-7-nitroquinoxaline-6-carbonitrile Chemical compound O=C1C(=O)N=C2C=C(C#N)C([N+](=O)[O-])=CC2=N1 IAWXTSMHXFRLQR-UHFFFAOYSA-N 0.000 description 1
- ZZYJIEWWTWIQGM-UHFFFAOYSA-N 3-ethoxy-4-[4-[3-(propan-2-ylsulfonylamino)thiophen-2-yl]phenyl]benzoic acid Chemical compound CCOC1=CC(C(O)=O)=CC=C1C1=CC=C(C2=C(C=CS2)NS(=O)(=O)C(C)C)C=C1 ZZYJIEWWTWIQGM-UHFFFAOYSA-N 0.000 description 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
- BWXCECYGGMGBHD-UHFFFAOYSA-M 6-(6,6-dimethyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-5-yl)-6h-furo[3,4-g][1,3]benzodioxol-8-one;bromide Chemical compound [Br-].C[N+]1(C)CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 BWXCECYGGMGBHD-UHFFFAOYSA-M 0.000 description 1
- 229940098747 AMPA receptor antagonist Drugs 0.000 description 1
- 239000000775 AMPA receptor antagonist Substances 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 229940098788 GABA receptor antagonist Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- PIMZUZSSNYHVCU-OMKDEKJRSA-N Picrotoxinin Natural products O=C1O[C@@H]2[C@@H](C(=C)C)[C@H]1[C@@]1(O)[C@@]3(C)[C@@H]2OC(=O)[C@@]23O[C@H]2C1 PIMZUZSSNYHVCU-OMKDEKJRSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IYGYMKDQCDOMRE-ZWKOTPCHSA-N bicuculline Chemical compound O([C@H]1[C@@H]2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-ZWKOTPCHSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 1
- 229960004381 flumazenil Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- SHLPPXXKRFINFY-UHFFFAOYSA-N isoquinolin-2-ium;bromide Chemical compound Br.C1=NC=CC2=CC=CC=C21 SHLPPXXKRFINFY-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- PIMZUZSSNYHVCU-YKWPQBAZSA-N picrotoxinin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2 PIMZUZSSNYHVCU-YKWPQBAZSA-N 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 150000008334 thiadiazines Chemical class 0.000 description 1
- USMNOWBWPHYOEA-MRTMQBJTSA-N α-thujone Chemical compound O=C([C@@H]1C)C[C@@]2(C(C)C)[C@@H]1C2 USMNOWBWPHYOEA-MRTMQBJTSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361834864P | 2013-06-13 | 2013-06-13 | |
| US61/834,864 | 2013-06-13 | ||
| PCT/US2014/042397 WO2014201411A1 (en) | 2013-06-13 | 2014-06-13 | Compositions and methods for treating metabolic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016521755A JP2016521755A (ja) | 2016-07-25 |
| JP2016521755A5 true JP2016521755A5 (enExample) | 2017-07-27 |
Family
ID=52022819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016519696A Pending JP2016521755A (ja) | 2013-06-13 | 2014-06-13 | 代謝障害を治療するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20150011554A1 (enExample) |
| EP (2) | EP3311842A1 (enExample) |
| JP (1) | JP2016521755A (enExample) |
| CN (1) | CN105579575A (enExample) |
| AU (1) | AU2014277952A1 (enExample) |
| BR (1) | BR112015031249A2 (enExample) |
| CA (1) | CA2915405A1 (enExample) |
| MX (1) | MX2015017253A (enExample) |
| WO (1) | WO2014201411A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| US20100035886A1 (en) | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
| US8741918B2 (en) | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
| EP2217073B1 (en) | 2007-06-21 | 2019-10-09 | VeroScience LLC | Method of treating metabolic disorders and depression with dopamine receptor agonists |
| US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
| US8431155B1 (en) | 2012-04-30 | 2013-04-30 | Veroscience Llc | Bromocriptine formulations |
| CN120713906A (zh) | 2016-04-20 | 2025-09-30 | 维罗技术有限责任公司 | 用于治疗代谢失调的组合物和方法 |
| PL3697418T3 (pl) | 2017-10-18 | 2025-02-03 | Veroscience Llc | Polepszone preparaty bromokryptyny |
| WO2019113110A2 (en) * | 2017-12-05 | 2019-06-13 | Peter Vanderklish | Modulation of ampa/kainate receptors for the treatment of hypoglycemia |
| WO2020236696A1 (en) * | 2019-05-23 | 2020-11-26 | Dignity Health | Inhibitory interneuron treatment methods, uses and compositions for diabetes |
| CA3149877A1 (en) | 2019-09-23 | 2021-04-01 | Anthony H. Cincotta | Method for inducing tumor regression |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3784703A (en) * | 1972-02-29 | 1974-01-08 | Merck & Co Inc | Method of treating hypertension |
| US5017566A (en) | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
| US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| US4939174A (en) | 1988-02-26 | 1990-07-03 | Shashoua Victor E | Appetite suppression with dopamine-fatty acid conjugates |
| US4933324A (en) | 1988-02-26 | 1990-06-12 | Shashoua Victor E | Fatty acid-neuroactive drug conjugate as a prodrug |
| US5344832A (en) * | 1990-01-10 | 1994-09-06 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates |
| CZ282909B6 (cs) * | 1991-12-23 | 1997-11-12 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Použití agonisty dopaminu a stimulátoru prolaktinu pro přípravu farmaceutického přípravku a tento farmaceutický přípravek |
| US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| EP1156043B1 (en) | 1992-07-24 | 2003-11-12 | The Regents Of The University Of California | Drugs that enhance synaptic responses mediated by ampa receptors |
| US20020099050A1 (en) | 1993-07-23 | 2002-07-25 | Lynch Gary S. | Drugs that enhance synaptic responses mediated by AMPA receptors |
| US6274600B1 (en) | 1995-06-05 | 2001-08-14 | The Regents Of The University Of California | Heteroatom substituted benzoyl derivatives that enhance synaptic responses mediated by AMPA receptors |
| US5488049A (en) | 1993-12-10 | 1996-01-30 | Fidia - Georgetown Institute For The Neuro-Sciences | Method of treating learning and memory disorders using benzothiadiazide derivatives as nootropic agents |
| US5852008A (en) | 1995-01-24 | 1998-12-22 | The Regents Of The University Of California | Heteroatom substituted benzoyl derivatives that enhance synaptic response mediated by receptors |
| US5650409A (en) | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| US5773434A (en) | 1995-08-30 | 1998-06-30 | Gary A. Rogers | Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia |
| US5686423A (en) * | 1996-02-16 | 1997-11-11 | Department Of Health, The Executive Yuan, Republic Of China | Di-and tri-peptide mimetic compounds for Parkinson's disease |
| US5891871A (en) | 1996-03-21 | 1999-04-06 | Cocensys, Inc. | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
| US5736543A (en) | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
| AU4416197A (en) | 1996-09-17 | 1998-04-14 | Regents Of The University Of California, The | Positive ampa receptor modulation to enhance brain neurotrophic factor expression |
| AU4345297A (en) | 1996-09-17 | 1998-04-14 | Regents Of The University Of California, The | Benzothiadiazide derivatives and their use as allosteric up-modulators of the ampa receptor |
| AU5106498A (en) * | 1996-10-22 | 1998-05-15 | Ergo Research Corporation | Method for increasing blood insulin levels in mammals |
| GB9702194D0 (en) | 1997-02-04 | 1997-03-26 | Lilly Co Eli | Sulphonide derivatives |
| US6110935A (en) | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| US6329368B1 (en) | 1997-05-09 | 2001-12-11 | The Regents Of The University Of California | Endocrine modulation with positive modulators of AMPA type glutamate receptors |
| US20050245612A1 (en) * | 2004-05-03 | 2005-11-03 | Blass John P | Pharmaceutical compositions for metabolic insufficiencies |
| US5985871A (en) | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
| CA2320354A1 (en) | 1998-02-18 | 1999-08-26 | Neurosearch A/S | Novel compounds and their use as positive ampa receptor modulators |
| US6943159B1 (en) | 1998-02-18 | 2005-09-13 | Neurosearch A/S | Compounds and their use as positive AMPA receptor modulators |
| AU741742B2 (en) | 1998-02-24 | 2001-12-06 | Eli Lilly And Company | Sulphonamide derivatives |
| US6174922B1 (en) | 1998-05-11 | 2001-01-16 | Eli Lilly And Company | Sulphonamide derivatives |
| WO1999044612A1 (en) | 1998-03-02 | 1999-09-10 | Cocensys, Inc. | Substituted quinazolines and analogs and the use thereof |
| US6107489A (en) | 1998-03-17 | 2000-08-22 | Conjuchem, Inc. | Extended lifetimes in vivo renin inhibitors |
| US6124278A (en) | 1998-04-03 | 2000-09-26 | The Regents Of The University Of California | Acylbenzoxazines for enhancing synaptic response |
| WO1999057119A1 (en) * | 1998-05-04 | 1999-11-11 | Neotherapeutics, Inc. | Novel dopamine-like 9-substituted hypoxanthine and methods of use |
| US6617351B1 (en) | 1998-07-31 | 2003-09-09 | Eli Lilly And Company | Amide, carbamate, and urea derivatives |
| AU5239899A (en) | 1998-07-31 | 2000-02-21 | Eli Lilly And Company | Amidophosphate derivatives |
| US6525099B1 (en) | 1998-07-31 | 2003-02-25 | Eli Lilly And Company | N-substituted sulfonamide derivatives |
| US6358981B1 (en) | 1998-07-31 | 2002-03-19 | Eli Lilly And Company | Sulphonamide derivatives |
| PE20000944A1 (es) | 1998-07-31 | 2000-09-20 | Lilly Co Eli | Derivados de sulfonamida |
| PE20000942A1 (es) | 1998-07-31 | 2000-09-28 | Lilly Co Eli | Derivados de amida, carbamato y urea |
| WO2000006159A1 (en) | 1998-07-31 | 2000-02-10 | Eli Lilly And Company | Heterocyclic sulphonamide derivatives |
| US6358982B1 (en) | 1998-07-31 | 2002-03-19 | Eli Lilly And Company | Heterocyclyl sulphonamide derivatives |
| CA2338994A1 (en) | 1998-07-31 | 2000-02-10 | Paul Leslie Ornstein | Sulfonamide derivatives |
| AU5233699A (en) | 1998-07-31 | 2000-02-21 | Eli Lilly And Company | Sulfonamide derivatives |
| PE20000943A1 (es) | 1998-07-31 | 2000-09-28 | Lilly Co Eli | Derivados de sulfonamida |
| AU5233999A (en) | 1998-07-31 | 2000-02-21 | Eli Lilly And Company | Alkenyl sulphonamide derivatives |
| NZ530385A (en) | 1999-04-30 | 2004-05-28 | Lilly Co Eli | Monofluoroalkyl derivatives |
| JP4761683B2 (ja) | 1999-06-04 | 2011-08-31 | ユーロ−セルティック エス． ア． | 置換５−オキソ−５，６，７，８−テトラヒドロ−４ｈ−１−ベンゾピランおよびベンゾチオピランならびにそのａｍｐａ増強剤としての使用 |
| US6297226B1 (en) | 1999-10-15 | 2001-10-02 | Neotherapeutics, Inc. | Synthesis and methods of use of 9-substituted guanine derivatives |
| EP1246797B1 (en) | 1999-12-08 | 2008-07-23 | Eli Lilly And Company | Cyclopentyl sulfonamide derivatives |
| US6639107B1 (en) | 1999-12-08 | 2003-10-28 | Eli Lilly And Company | Cyclopentyl sulfonamide derivatives |
| DE10004572A1 (de) | 2000-02-02 | 2001-08-09 | Boehringer Ingelheim Pharma | Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| JP2003527369A (ja) | 2000-03-13 | 2003-09-16 | イーライ・リリー・アンド・カンパニー | スルホンアミド誘導体 |
| US7345031B2 (en) * | 2000-04-12 | 2008-03-18 | International Medical Innovations, Inc. | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use |
| MXPA02010021A (es) | 2000-05-19 | 2003-02-12 | Lilly Co Eli | Derivados de sulfonamida. |
| DZ3343A1 (fr) | 2000-05-19 | 2001-11-29 | Lilly Co Eli | Derives de sulfonamide |
| EP1292571A2 (en) | 2000-06-06 | 2003-03-19 | Eli Lilly And Company | (bis)sulfonamide derivatives |
| ES2225558T3 (es) | 2000-06-13 | 2005-03-16 | Eli Lilly And Company | Derivados de sulfonamida. |
| EP1309577A2 (en) | 2000-08-11 | 2003-05-14 | Eli Lilly And Company | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function |
| AU2001280470A1 (en) | 2000-08-11 | 2002-02-25 | Eli Lilly And Company | Heterocyclic sulfonamide derivatives |
| US20040198833A1 (en) | 2000-08-31 | 2004-10-07 | Bender David Michael | Acetylenic sulfonamide derivatives |
| JP2004511540A (ja) | 2000-10-13 | 2004-04-15 | イーライ・リリー・アンド・カンパニー | シクロアルキルフルオロスルホンアミド誘導体 |
| WO2002049636A1 (en) * | 2000-12-19 | 2002-06-27 | Rajagopal Thiruvengadam | An antidiabetic composition of amino acids |
| AU2002307327A1 (en) * | 2001-05-04 | 2002-11-18 | Eli Lilly And Company | Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes |
| ITBO20010271A1 (it) | 2001-05-08 | 2002-11-08 | Giuseppe Cannazza | Metodo per il trattamento e la prevenzione dei disturbi del sistema nervoso centrale associati ad una alterazione della neurotrasmissione gl |
| US20030100552A1 (en) | 2001-05-17 | 2003-05-29 | Boehringer Ingelheim Pharma Kg | Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions |
| US20040157817A1 (en) | 2001-05-30 | 2004-08-12 | Cantell Buddy Eugene | Cycloalkenylsulfonamide derivatives |
| CA2446716A1 (en) | 2001-06-05 | 2002-12-12 | Eli Lilly And Company | Sulfonamide derivatives |
| TWI232863B (en) | 2001-06-11 | 2005-05-21 | Akzo Nobel Nv | Benzoxazepine derivatives |
| EP1414423A1 (de) * | 2001-07-31 | 2004-05-06 | Lothar Saiger | Mittel zur behandlung von depressionen enthaltend ein lokalanästhetikum |
| US7045543B2 (en) * | 2001-11-05 | 2006-05-16 | Enzrel Inc. | Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites |
| PL371722A1 (en) | 2001-11-26 | 2005-06-27 | Cortex Pharmaceuticals, Inc. | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses |
| US7862807B2 (en) * | 2002-07-19 | 2011-01-04 | University Of California, San Diego | Dendrimers as molecular translocators |
| US20080200453A1 (en) * | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US9655865B2 (en) * | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| US20050054652A1 (en) * | 2002-07-29 | 2005-03-10 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
| FR2854634B1 (fr) | 2003-05-05 | 2005-07-08 | Servier Lab | Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US7625932B2 (en) | 2003-10-08 | 2009-12-01 | Eli Lilly And Company | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors |
| GB0407583D0 (en) * | 2004-04-05 | 2004-05-05 | Arbab Tarig S M | Diagnostic testing and related matters |
| EP1752146A4 (en) * | 2004-05-19 | 2007-10-10 | Ajinomoto Kk | THERAPEUTIC AGENT AGAINST DIABETES |
| US7342131B2 (en) | 2004-06-04 | 2008-03-11 | Xenoport, Inc. | Levodopa prodrugs, and compositions and uses thereof |
| GB0417709D0 (en) | 2004-08-09 | 2004-09-08 | Glaxo Group Ltd | Compounds |
| US20070270471A1 (en) | 2004-08-09 | 2007-11-22 | Glaxo Group Limited | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine |
| AU2005270377A1 (en) | 2004-08-09 | 2006-02-16 | Glaxo Group Limited | Compounds which potentiate glutamate receptor and uses thereof in medicine |
| US20060167099A1 (en) * | 2004-11-09 | 2006-07-27 | Anat Biegon | Use of compositions that increase glutamate receptor activity in treatment of brain injury |
| JP2008530162A (ja) | 2005-02-15 | 2008-08-07 | グラクソ グループ リミテッド | グルタミン酸受容体を増強する化合物および医薬におけるそれらの使用 |
| AU2006215703A1 (en) * | 2005-02-17 | 2006-08-24 | Instituto Del Metabolismo Celular, S.L. | L-aspartic acid for the treatment of problems in connection with the fat or glucose metabolism |
| DE602006003661D1 (de) | 2005-06-06 | 2008-12-24 | Lilly Co Eli | Ampa-rezeptoren-verstärker |
| WO2006138243A2 (en) * | 2005-06-13 | 2006-12-28 | University Of Vermont And State Agricultural College | Inhibition of creatine uptake to promote weight loss |
| ES2761812T3 (es) * | 2005-11-22 | 2020-05-21 | Nalpropion Pharmaceuticals Inc | Composición y métodos de aumento de la sensibilidad a la insulina |
| US20090286797A1 (en) | 2005-11-22 | 2009-11-19 | Dan Peters | Novel Quinoxaline Derivatives and Their Medical Use |
| GB0602560D0 (en) | 2006-02-08 | 2006-03-22 | Glaxo Group Ltd | Compounds |
| US20090221643A1 (en) | 2006-02-08 | 2009-09-03 | Kevin Michael Thewlis | 4-phenyl-3-(2-propylsulfonylamino) tetrahydrofuran derivatives which potentiate glutamate receptors and are useful in the treatment of schizophrenia |
| TW200843732A (en) | 2006-12-21 | 2008-11-16 | Xenoport Inc | Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use |
| US7829592B2 (en) | 2006-12-21 | 2010-11-09 | Xenoport, Inc. | Catechol protected levodopa diester prodrugs, compositions, and methods of use |
| GB0711088D0 (en) * | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| US8741918B2 (en) * | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
| GB0721094D0 (en) * | 2007-10-26 | 2007-12-05 | Glaxo Group Ltd | Compounds |
| GB0721092D0 (en) * | 2007-10-26 | 2007-12-05 | Glaxo Group Ltd | Compounds |
| JP5597555B2 (ja) * | 2008-03-12 | 2014-10-01 | ユニバーシティー・オブ・マイアミ | 低血糖症を治療するための医薬品の製造におけるグルカゴン放出を刺激する化合物の使用 |
| WO2010015037A1 (en) * | 2008-08-08 | 2010-02-11 | Howard Florey Institute | Therapeutic methods and compositions |
| US8399513B2 (en) | 2008-10-20 | 2013-03-19 | Xenoport, Inc. | Levodopa prodrug mesylate hydrate |
| GB0821166D0 (en) * | 2008-11-19 | 2008-12-24 | Glaxo Group Ltd | Compounds |
| GB0822425D0 (en) * | 2008-12-09 | 2009-01-14 | Glaxo Group Ltd | Compounds |
| US8685372B2 (en) * | 2009-04-15 | 2014-04-01 | The Regents Of The University Of California | Peptides and aptamers for targeting of neuron or nerves |
| US10206921B2 (en) | 2009-06-03 | 2019-02-19 | The Regents Of The University Of California | Methods and compositions for treating a subject for central nervous system (CNS) injury |
| WO2011053869A2 (en) * | 2009-10-31 | 2011-05-05 | The Regents Of The University Of California | Manipulation of brain in a circuit-specific manner |
| SI2603513T1 (sl) * | 2010-08-10 | 2020-07-31 | Takeda Pharmaceutical Company Limited | Heterociklična spojina in njena uporaba kot pozitivni alosterični modulator receptorja AMPA |
| US8697898B2 (en) | 2011-11-23 | 2014-04-15 | Instytut Medycyny Doswiadczalnej i Klinicznej im. M. Mossakowskiego PAN | Medical application of lipid derivatives of dopamine and the methods of their production |
-
2014
- 2014-06-13 BR BR112015031249A patent/BR112015031249A2/pt not_active Application Discontinuation
- 2014-06-13 JP JP2016519696A patent/JP2016521755A/ja active Pending
- 2014-06-13 EP EP17206128.5A patent/EP3311842A1/en not_active Withdrawn
- 2014-06-13 AU AU2014277952A patent/AU2014277952A1/en not_active Abandoned
- 2014-06-13 MX MX2015017253A patent/MX2015017253A/es unknown
- 2014-06-13 CA CA2915405A patent/CA2915405A1/en not_active Abandoned
- 2014-06-13 CN CN201480044899.5A patent/CN105579575A/zh active Pending
- 2014-06-13 EP EP14811295.6A patent/EP3008167A4/en not_active Withdrawn
- 2014-06-13 US US14/304,659 patent/US20150011554A1/en not_active Abandoned
- 2014-06-13 WO PCT/US2014/042397 patent/WO2014201411A1/en not_active Ceased
-
2018
- 2018-11-16 US US16/193,193 patent/US20190160059A1/en not_active Abandoned
-
2022
- 2022-01-04 US US17/568,560 patent/US20220142960A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108883108B (zh) | 马赛替尼用于治疗肌萎缩侧索硬化症患者亚群的用途 | |
| JP4850880B2 (ja) | 疼痛の処置のためのエピナスチンの使用 | |
| EP3730140B1 (en) | Tradipitant for use in treating nausea or vomiting | |
| KR101900520B1 (ko) | 복합 조성물 | |
| RU2008150622A (ru) | Лечение агонистом мелатонина | |
| JP2010526837A5 (enExample) | ||
| US20200383983A1 (en) | Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo | |
| JP2018522920A5 (enExample) | ||
| BR112019020100A2 (pt) | composições e métodos para tratar sinucleinopatias | |
| JP2016505050A5 (enExample) | ||
| Arima et al. | Positive effect of baclofen on body weight reduction in obese subjects: a pilot study | |
| BR112019022175A2 (pt) | Composições e método para tratamento de depressão | |
| RU2013112890A (ru) | Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина | |
| CA2963179C (en) | Levosimendan for use in the treatment of motor neuron diseases (als) | |
| Zesiewicz et al. | Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease | |
| Minton | Volunteer models for predicting antiemetic activity of 5‐HT3‐receptor antagonists. | |
| AU2014360366A1 (en) | Treatment of spasticity with intrathecal dantrolene | |
| US6489356B2 (en) | Method for treating pain in humans | |
| BR112020016672A2 (pt) | Leucina, acetil-leucina ou um sal farmaceuticamente aceitável da mesma e método de reduzir, inibir ou eliminar um ou mais sintomas de síndrome das pernas inquietas (rls) em um indivíduo em necessidade do mesmo | |
| JP2020527156A5 (enExample) | ||
| Serafini et al. | The use of rotigotine in the treatment of restless legs syndrome | |
| WO2013091334A1 (zh) | 雷帕霉素在制备治疗精神分裂症药物中的应用 | |
| Ding et al. | Ketamine as a rapid-acting antidepressant: A scoping review of mechanisms and efficacy in treatment-resistant depression | |
| JP6869893B2 (ja) | 前頭葉機能障害治療剤 | |
| RU2010122438A (ru) | Противовирусное средство для профилактики и лечения клещевого энцефалита |